Key Highlights

  • Shares of Eli Lilly (NYSE:LLY) finished the November 4, 2026 session at USD 1,417.99, a gain of 0.61%, with 3.64 million shares traded for about USD 5.2 billion, which ranked nineteenth by value on the most-active screen.
  • Relative Volume reached 1.25, and the screen listed roughly USD 1,334 billion of market value, a trailing P/E of 46.59 plus diluted EPS of USD 30.44, up 50.54% across twelve months.
  • Competitor Novo Nordisk lifted its outlook on November 4, news that buoyed obesity drug stocks that day.
  • Lilly closed down 3.55% at USD 1,364.73 on November 5, and no company announcement accompanied the decline.

What Made Lilly Active on November 4

Eli Lilly was among the few heavyweights to edge higher during a session of sharp moves elsewhere. Healthcare ranked among the firmer sectors after the midterms, since investors anticipated a more favorable policy climate, and hospital and insurer stocks rallied hard. Lilly also gained from developments at its chief rival: Novo Nordisk released third-quarter results, raised its outlook and reported strong sales of its oral weight-loss pill, reinforcing the view that obesity drug Demand remains large. The 0.61% advance was modest, yet with a single share priced above USD 1,400, the stock still changed hands for about USD 5.2 billion and earned a place on the most-active list. Relative volume of 1.25 signals moderate interest. Drugmakers with hefty cash flows often serve as steady holdings when growth names swing, which encouraged steady buying in the first session.

The November 5 Retreat and Its Drivers

The next session brought a 3.55% drop to USD 1,364.73, a session in which the Nasdaq Composite dropped 5.52% while healthcare shares lost over 2.5%. No single company announcement accounts for the decline. Commentary cited valuation, since the shares sit close to 39 times forward profit estimates and roughly 46 times trailing earnings, along with rivalry in obesity and diabetes treatments and institutional profit-taking after a long rally. Third-quarter figures discussed in market coverage showed worldwide realized prices down 15%, with international prices off 29% because discounted access schemes, such as a Medicare bridge covering GLP-1 treatments, came into play, and sales of its oral drug Foundayo at USD 184 million, short of the USD 217 million forecast. Mounjaro and Zepbound jointly make up roughly two thirds of sales. Shareholders also consider that Lilly commands about a quarter of the oral weight-loss market, against the approximately three quarters held by the Danish competitor, which makes the new pill a decisive trial for share.

Pricing Pressure, Competition and Oral Drug Uptake

Key hazards: government-driven price pressure, rivalry from Novo Nordisk's oral pill, reliance on two injectable medicines and an elevated valuation. Roughly USD 2 billion of non-recurring 2026 Revenue will also make 2027 year-over-year comparisons tougher. Trailing diluted EPS of USD 30.44, up 50.54%, underscores the business's strength. Track weekly prescription trends, uptake of the oral drug, progress on new obesity therapies and any changes to Medicare coverage rules under the incoming Congress. Fourth-quarter numbers should indicate if higher volume can counterbalance weaker pricing, and oral uptake is a further gauge.

Where Things Stand

Eli Lilly made the most-active list on November 4, helped by a lofty share price that turns modest volume into billions of dollars in trading, while rival Novo Nordisk's guidance increase lifted the wider group. A slight 0.61% rise on November 4 gave way to a 3.55% slump on November 5, which came without any company-specific news. Pricing pressure and how quickly the oral pill gains users now set the tone for the shares. Prescription data will reveal demand.